An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
Clinical trial NCT03828292 · COMPLETED
Trial details
- NCT number
- NCT03828292
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-14
- Primary completion
- 2023-04-06
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.